AlectorALEC
ALEC
About: Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.
Employees: 241
0
Funds holding %
of 7,139 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
154% more call options, than puts
Call options by funds: $399K | Put options by funds: $157K
21% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 38
0% more funds holding in top 10
Funds holding in top 10: 3 [Q3] → 3 (+0) [Q4]
2.47% less ownership
Funds ownership: 77.35% [Q3] → 74.88% (-2.47%) [Q4]
8% less funds holding
Funds holding: 159 [Q3] → 146 (-13) [Q4]
26% less first-time investments, than exits
New positions opened: 29 | Existing positions closed: 39
61% less capital invested
Capital invested by funds: $351M [Q3] → $139M (-$213M) [Q4]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$3
60%
upside
Avg. target
$4
114%
upside
High target
$5
167%
upside
3 analyst ratings
1 positive
33%
1 neutral
33%
1 negative
33%
Stifel Paul Matteis 14% 1-year accuracy 2 / 14 met price target | 114%upside $4 | Hold Downgraded | 16 Dec 2024 |
Morgan Stanley Matthew Harrison 50% 1-year accuracy 10 / 20 met price target | 60%upside $3 | Underweight Downgraded | 26 Nov 2024 |
BTIG Thomas Shrader 43% 1-year accuracy 3 / 7 met price target | 167%upside $5 | Buy Maintained | 26 Nov 2024 |
Financial journalist opinion
Neutral
GlobeNewsWire
2 days ago
Alector to Host Fourth Quarter and Full-Year 2024 Earnings Conference Call
SOUTH SAN FRANCISCO, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced it will host a conference call and webcast on Wednesday, February 26, 2025, at 4:30 p.m.
Neutral
GlobeNewsWire
1 month ago
Alector Reports on Recent Progress and Outlines Strategic Priorities for 2025
Continue to advance preclinical and research pipeline, including key programs selectively combined with Alector Brain Carrier, enhancing the company's commitment to developing genetically-validated therapies for neurodegeneration
Negative
Benzinga
2 months ago
Neurology-Focused Alector Downgraded On Failed Alzheimer's Study, BofA Securities Highlights Lack Of Catalysts
Bank of America Securities has downgraded Alector, Inc. ALEC, citing the failure of its AL002 program.
Negative
Zacks Investment Research
2 months ago
ALEC Stock Tanks as Alzheimer's Drug Fails in Mid-Stage Study
Alector stock falls as the phase II INVOKE-2 study evaluating AL002 in slowing disease progression in early Alzheimer's disease fails to meet the primary goal.
Negative
Benzinga
2 months ago
Alector/AbbVie-Partnered Alzheimer's Drug Disappoints In Mid-Stage Study; Alector Lays Off 17% Of Workforce
On Monday, Alector, Inc. ALEC released results from the INVOKE-2 Phase 2 trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer's disease (AD).
Neutral
GlobeNewsWire
2 months ago
Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer's Disease and Provides Business Update
SOUTH SAN FRANCISCO, Calif., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically validated therapies for the treatment of neurodegenerative diseases, today announced results from the INVOKE-2 Phase 2 clinical trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer's disease (AD). Treatment with AL002 resulted in sustained target engagement and pharmacodynamic responses indicative of microglial activation. However, AL002 failed to meet the primary endpoint of slowing of Alzheimer's clinical progression as measured by the Clinical Dementia Rating Sum of Boxes (CDR®-SB), and there were no treatment effects that favored AL002 on secondary clinical and functional endpoints. Similarly, there were no significant effects on Alzheimer's fluid biomarkers favoring AL002, and amyloid PET imaging demonstrated no treatment-related reduction of brain amyloid levels. As previously reported, MRI changes resembling amyloid-related imaging abnormalities (ARIA) and infusion-related reactions were observed in INVOKE-2. The instances of ARIA were primarily seen in participants treated with AL002.
Neutral
GlobeNewsWire
3 months ago
Alector Secures Flexible Credit Facility for Up to $50 Million From Hercules Capital
SOUTH SAN FRANCISCO, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that the Company has entered into a debt financing agreement with Hercules Capital, Inc. (NYSE: HTGC) for up to $50 million.
Negative
Zacks Investment Research
3 months ago
Alector (ALEC) Reports Q3 Loss, Misses Revenue Estimates
Alector (ALEC) came out with a quarterly loss of $0.43 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compares to loss of $0.53 per share a year ago.
Neutral
GlobeNewsWire
3 months ago
Alector Reports Third Quarter 2024 Financial Results and Provides Business Update
Data from INVOKE-2, evaluating TREM2 agonist candidate AL002 in patients with early Alzheimer's disease (AD), on track for 2024
Neutral
GlobeNewsWire
5 months ago
Alector to Participate in Upcoming Healthcare Conferences
SOUTH SAN FRANCISCO, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will participate in the following upcoming investor conferences:
Charts implemented using Lightweight Charts™